녹색사슬알균 균혈증 환자에서 감염성 심내막염의 관련인자와 사망의 예측인자
Factors Associated with Infective Endocarditis and Predictors of 3-month mortality of Patients with Viridans Streptococcal Bacteremia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Viridans streptococci is a major pathogen of infective endocarditis. This study was conducted in order to investigate the factors associated with infective endocarditis and predictors for three-month mortality among patients with viridans streptococcal bacteremia (VSB). Materials and Methods: In this study, among 261 eligible patients diagnosed as VSB from January 2000 through June 2011 in a university-affiliated hospital, a retrospective analysis of 197 patients was conducted. All patients with VSB were classified into two groups according to sites of bacteremia; infective endocarditis and other infections. Demographic and clinical characteristics were reviewed through electronic medical records factors associated with infective endocarditis and predictors of three-month mortality in VSB patients were evaluated. Results: Of the 197 patients, 37 (18.8%) patients had viridans streptococcal infective endocarditis (VSIE) and 160 (81.2%) patients had VSB due to other infection. In logistic regression analysis, underlying valvular heart disease (odds ratio [OR],48.43; 95% confidence interval [CI], 5.77-406.38) and persistent bacteremia (OR,46.32; 95% CI, 7.18-299.01) showed an independent association with VSIE. Threemonth mortality rate was 21.7% in patients with VSB. In logistic regression analysis,previous steroid use (OR, 9.31; 95% CI, 1.34-64.52), previous immunosuppressive therapy (OR, 9.50; 95% CI, 2.13-42.30), hypotension at onset of bacteremia (OR,7.72, 95% CI, 2.45-24.33), and Charlson comorbidity score ≥3 (OR, 4.53, 95% CI,1.55-13.28) showed an independent association with three-month mortality in patients with VSB. Conclusions: VSB patients who have valvular heart disease or persistent bacteremia routinely require echocardiography. Previous steroid use, immunosuppressive therapy, hypotension, and higher Charlson comorbidity score suggested poor prognosis in patients with VSB.
Abstract
Background: Viridans streptococci is a major pathogen of infective endocarditis. This study was conducted in order to investigate the factors associated with infective endocarditis and predictors for three-month mortality among patients with viridans streptococcal bacteremia (VSB). Materials and Methods: In this study, among 261 eligible patients diagnosed as VSB from January 2000 through June 2011 in a university-affiliated hospital, a retrospective analysis of 197 patients was conducted. All patients with VSB were classified into two groups according to sites of bacteremia; infective endocarditis and other infections. Demographic and clinical characteristics were reviewed through electronic medical records factors associated with infective endocarditis and predictors of three-month mortality in VSB patients were evaluated. Results: Of the 197 patients, 37 (18.8%) patients had viridans streptococcal infective endocarditis (VSIE) and 160 (81.2%) patients had VSB due to other infection. In logistic regression analysis, underlying valvular heart disease (odds ratio [OR],48.43; 95% confidence interval [CI], 5.77-406.38) and persistent bacteremia (OR,46.32; 95% CI, 7.18-299.01) showed an independent association with VSIE. Threemonth mortality rate was 21.7% in patients with VSB. In logistic regression analysis,previous steroid use (OR, 9.31; 95% CI, 1.34-64.52), previous immunosuppressive therapy (OR, 9.50; 95% CI, 2.13-42.30), hypotension at onset of bacteremia (OR,7.72, 95% CI, 2.45-24.33), and Charlson comorbidity score ≥3 (OR, 4.53, 95% CI,1.55-13.28) showed an independent association with three-month mortality in patients with VSB. Conclusions: VSB patients who have valvular heart disease or persistent bacteremia routinely require echocardiography. Previous steroid use, immunosuppressive therapy, hypotension, and higher Charlson comorbidity score suggested poor prognosis in patients with VSB.
참고문헌 (20)
- Ergin A., "Classical and new approaches in laboratory diagnosis of viridans streptococci", Mikrobiyol Bul, 44, pp.495~503 (2010)
- Bochud PY., "Bacteremia due to viridans streptococci in neutropenic patients : a review", Am J Med, 97, pp.256~264 (1994)
- Singh KP., "Clinically significant Streptococcus anginosus(Streptococcus milleri)infections : a review of 186 cases", N Z Med J, 101, pp.813~816 (1988)
- Wilson WR., "Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association", JAMA, 274, pp.1706~1713 (1995)
- Tunkel AR., "Infections caused by viridans streptococci in patients with neutropenia", Clin Infect Dis, 34, pp.1524~1529 (2002)
- Shenep JL., "Viridans-group streptococcal infections in immunocompromised hosts", Int J Antimicrob Agents, 14, pp.129~135 (2000)
- Steckelberg JM., "Risk factors for infective endocarditis", Infect Dis Clin North Am, 7, pp.9~19 (1993)
- Mylonakis E., "Infective endocarditis in adults", N Engl J Med, 345, pp.1318~1330 (2001)
- Chen PL., "A simple scoring algorithm predicting vascular infections in adults with nontyphoid Salmonella bacteremia", Clin Infect Dis, 55, pp.194~200 (2012)
- Hill EE., "Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia", Mayo Clin Proc, 82, pp.1165~1169 (2007)
- Lamas CC., "Bicuspid aortic valve--A silent danger : analysis of 50 cases of infective endocarditis", Clin Infect Dis, 30, pp.336~341 (2000)
- Gersony WM., "Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect", Circulation, 87(2 Suppl), pp.121~126 (1993)
- Li W., "Infective endocarditis in the grown-up congenital heart(GUCH)population", Eur Heart J, 19, pp.166~173 (1998)
- Bosshard PP., "Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction : a 3-year experience", Clin Infect Dis, 37, pp.167~172 (2003)
- Fowler VG Jr., "Clinical identifiers of complicated Staphylococcus aureus bacteremia", Arch Intern Med, 163, pp.2066~2072 (2003)
- Chang FY., "Staphylococcus aureus bacteremia : recurrence and the impact of antibiotic treatment in a prospective multicenter study", Medicine(Baltimore), 82, pp.333~339 (2003)
- Hsu RB., "Risk factors for nosocomial infective endocarditis in patients with methicillin-resistant Staphylococcus aureus bacteremia", Infect Control Hosp Epidemiol, 26, pp.654~657 (2005)
- Kaech C., "Course and outcome of Staphylococcus aureus bacteraemia : a retrospective analysis of 308 episodes in a Swiss tertiary-care centre", Clin Microbiol Infect, 12, pp.345~352 (2006)
- Mrazova M., "Prospective national survey of viridans streptococcal bacteraemia risk factors, antibacterial susceptibility and outcome of 120 episodes", Scand J Infect Dis, 37, pp.637~641 (2005)
- Spanik S., "Viridans streptococcal bacteraemia due to penicillinresistant and penicillin-sensitive streptococci : analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis", Scand J Infect Dis, 29, pp.245~249 (1997)